Aura Biosciences (AURA) files Form 3 for Chief People Officer Julie Person

Rhea-AI Filing Summary

Aura Biosciences, Inc. filed an initial statement of beneficial ownership for Julie Person, who is identified as the company's Chief People Officer. The filing is a registration of her status as an officer and reports no transactions or holdings in company securities at this time.

FAQ

What does Aura Biosciences (AURA) disclose about Julie Person in this Form 3?

Aura Biosciences identifies Julie Person as a reporting person and notes she is the company's Chief People Officer. The Form 3 establishes her status as an officer subject to beneficial ownership reporting rules.

Does the Aura Biosciences (AURA) Form 3 for Julie Person show any stock transactions?

No. The Form 3 for Julie Person reports no transactions, with buy, sell, exercise, gift, and other transaction counts all shown as zero in the transaction summary data.

Are any Aura Biosciences (AURA) share holdings reported for Julie Person on this Form 3?

No share or derivative holdings are reported for Julie Person. The data show 0 holding entries and an empty derivative position summary, indicating no positions are listed in this initial filing.

Is there any indication of a Rule 10b5-1 plan in the Aura Biosciences (AURA) Form 3?

There is no indication of a Rule 10b5-1 trading plan for Julie Person in this Form 3. The plan-related field is shown as null, and no footnote cites a trading plan.

What role does Julie Person hold at Aura Biosciences (AURA) according to this filing?

Julie Person is reported as an officer of Aura Biosciences with the title Chief People Officer. The Form 3 filing triggers her ongoing obligation to report future changes in beneficial ownership of company securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/12/2026 - 04:17 PM Accepted by SEC EDGAR 08/12/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Person Julie

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/12/2026

3. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Amy Elazzouzi, as Attorney-in-Fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)